Skip to main content
OpenTrials

Clinical trial condition

Mastocytosis

Explore clinical trials studying Mastocytosis. Study availability and eligibility vary by location and protocol.

60 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Mastocytosis trial results

Completed

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

NCT00666211

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +108 more
Locations
  • Jennie Stuart Medical Center Hopkinsville, Kentucky, United States
  • Mitchell Memorial Cancer Center at Owensboro Medical Health System Owensboro, Kentucky, United States
  • Erlanger Health System Chattanooga, Tennessee, United States
  • Tennessee Plateau Oncology Crossville, Tennessee, United States
View Trial Details
Completed

Efficacy and Safety of TF002 in Cutaneous Mastocytosis

NCT00457288

Conditions
Cutaneous Mastocytosis, Immune System Diseases, Mast Cell Activation Disorders, +10 more
Locations
  • Klinik und Poliklinik für Dermatologie und Venerologie der Universität Cologne, Köln, Germany
  • Universitäts-Hautklinik Mainz, Germany
  • Klinik und Poliklinik für Dermatologie und Allergologie der LMU München, Germany
  • Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein der TU München, Germany
View Trial Details
Active, Not Recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Chronic Disease, +37 more
Locations
  • Colorado Blood Cancer Network Denver, Colorado, United States
  • University of Maryland, Greenbaum Comprehensive Cancer Center Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • START - Midwest Grand Rapids, Michigan, United States
View Trial Details
Active, Not Recruiting

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260

Conditions
Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +6 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • Stanford Cancer Institute Stanford, California, United States
  • Mayo Clinic Florida Jacksonville, Florida, United States
View all 49 locations
View Trial Details

Related conditions